Product Description
ATI-1701 is a vaccine that is designed to work against the bacteria Francisella tularensis, which the U.S. National Institutes of Health (NIH) defines as a Category A pathogen (an organism that poses the highest risk to national security and public health). As it is 1000x more infectious than anthrax, the aerosolized form is considered to have a high potential for use in a bioterrorist attack. Successfully weaponized and likely deployed in the 20th Century, several countries may already have operational weapons programs leveraging this pathogen. In preclinical studies, ATI-1701 demonstrated 100% protection from aerosolized weapons-grade F. tularensis, as compared to a 30% protection from the only vaccine currently used (but not FDA approved) for prevention of disease. Appili will continue developing ATI-1701 under the FDA’s Animal Rule, which can reduce the amount of human clinical testing required for market approval. (Sourced from: https://www.appilitherapeutics.com/ati-1701)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Appili
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Tularemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|